Format
Sort by
Items per page

Send to

Choose Destination

Search Tip

Sort by Best Match to display results from highest to lowest relevance to your search terms.

Try it Now

Search results

Items: 1 to 20 of 199

1.

Nucleotide excision repair (NER) is a potential therapeutic target in multiple myeloma.

Szalat R, Samur MK, Fulciniti M, Lopez M, Nanjappa P, Cleynen A, Wen K, Kumar S, Perrini T, Calkins AS, Reznichenko E, Chauhan D, Tai YT, Shammas M, Fermand JP, Arnulf B, Avet-Loiseau H, Lazaro JB, Munshi NC.

Leukemia. 2017 Jun 7. doi: 10.1038/leu.2017.182. [Epub ahead of print]

PMID:
28588253
2.

Plasma exchanges for severe acute neurological deterioration in patients with IgM anti-myelin-associated glycoprotein (anti-MAG) neuropathy.

Baron M, Lozeron P, Harel S, Bengoufa D, Vignon M, Asli B, Malphettes M, Parquet N, Brignier A, Fermand JP, Kubis N, Arnulf B.

J Neurol. 2017 Jun;264(6):1132-1135. doi: 10.1007/s00415-017-8502-3. Epub 2017 May 8.

PMID:
28484839
3.

[Classification and therapeutic management of monoclonal gammopathies of renal significance].

Javaugue V, Bouteau I, Sirac C, Quellard N, Diolez J, Colombo A, Desport E, Ecotière L, Goujon JM, Fermand JP, Touchard G, Jaccard A, Bridoux F.

Rev Med Interne. 2017 Apr 27. pii: S0248-8663(17)30105-4. doi: 10.1016/j.revmed.2017.03.012. [Epub ahead of print] French.

PMID:
28457684
4.

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.

Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P; IFM 2009 Study.

N Engl J Med. 2017 Apr 6;376(14):1311-1320. doi: 10.1056/NEJMoa1611750.

PMID:
28379796
5.

Non-cirrhotic portal hypertension in necrobiotic xanthogranuloma associated with monoclonal gammopathy.

Vignon M, Placais L, Malphettes M, Bouaziz JD, Asli B, Bedossa P, Rivet J, Szalat R, Zagdanski AM, Rybojad M, Fermand JP, Baron M, Rautou PE, Arnulf B.

J Eur Acad Dermatol Venereol. 2017 Mar 10. doi: 10.1111/jdv.14213. [Epub ahead of print] No abstract available.

PMID:
28295661
6.

Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.

Bridoux F, Javaugue V, Bender S, Leroy F, Aucouturier P, Debiais-Delpech C, Goujon JM, Quellard N, Bonaud A, Clavel M, Trouillas P, Di Meo F, Gombert JM, Fermand JP, Jaccard A, Cogné M, Touchard G, Sirac C.

Kidney Int. 2017 Feb;91(2):423-434. doi: 10.1016/j.kint.2016.09.004. Epub 2016 Oct 20.

PMID:
27773425
7.

Schnitzler syndrome: validation and applicability of diagnostic criteria in real-life patients.

Gusdorf L, Asli B, Barbarot S, Néel A, Masseau A, Puéchal X, Gottenberg JE, Grateau G, Blanchard-Delaunay C, Rizzi R, Lifermann F, Kyndt X, Aubin F, Bessis D, Boye T, Gayet S, Rongioletti F, Sauleau E, Fermand JP, Lipsker D.

Allergy. 2017 Feb;72(2):177-182. doi: 10.1111/all.13035. Epub 2016 Sep 12. Review.

PMID:
27564982
8.

Exclusion of Patients with a Severe T-Cell Defect Improves the Definition of Common Variable Immunodeficiency.

Bertinchamp R, Gérard L, Boutboul D, Malphettes M, Fieschi C, Oksenhendler E; DEFI study group.

J Allergy Clin Immunol Pract. 2016 Nov - Dec;4(6):1147-1157. doi: 10.1016/j.jaip.2016.07.002. Epub 2016 Aug 10.

PMID:
27522107
9.

Current anti-myeloma therapies in renal manifestations of monoclonal light chain-associated Fanconi syndrome: a retrospective series of 49 patients.

Vignon M, Javaugue V, Alexander MP, El-Karoui K, Karras A, Roos-Weil D, Royer B, Asli B, Knebelmann B, Touchard G, Jaccard A, Arnulf B, Bridoux F, Leung N, Fermand JP.

Leukemia. 2017 Jan;31(1):123-129. doi: 10.1038/leu.2016.195. Epub 2016 Jul 20.

PMID:
27435002
10.

Pharmacokinetics, safety, and efficacy of lenalidomide plus dexamethasone in patients with multiple myeloma and renal impairment.

Bridoux F, Chen N, Moreau S, Arnulf B, Moumas E, Abraham J, Desport E, Jaccard A, Fermand JP.

Cancer Chemother Pharmacol. 2016 Jul;78(1):173-82. doi: 10.1007/s00280-016-3068-9. Epub 2016 Jun 10.

PMID:
27286995
11.

[Randall-type monoclonal immunoglobulin deposition disease: From diagnosis to treatment].

Cohen C, Javaugue V, Joly F, Arnulf B, Fermand JP, Jaccard A, Sirac C, Knebelmann B, Bridoux F, Touchard G.

Nephrol Ther. 2016 Jun;12(3):131-9. doi: 10.1016/j.nephro.2015.12.005. Epub 2016 Apr 21. French.

PMID:
27117766
12.

VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial.

Moreau P, Hulin C, Macro M, Caillot D, Chaleteix C, Roussel M, Garderet L, Royer B, Brechignac S, Tiab M, Puyade M, Escoffre M, Stoppa AM, Facon T, Pegourie B, Chaoui D, Jaccard A, Slama B, Marit G, Laribi K, Godmer P, Luycx O, Eisenmann JC, Allangba O, Dib M, Araujo C, Fontan J, Belhadj K, Wetterwald M, Dorvaux V, Fermand JP, Rodon P, Kolb B, Glaisner S, Malfuson JV, Lenain P, Biron L, Planche L, Caillon H, Avet-Loiseau H, Dejoie T, Attal M.

Blood. 2016 May 26;127(21):2569-74. doi: 10.1182/blood-2016-01-693580. Epub 2016 Mar 21.

13.

Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.

Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Michel Goujon J, Fermand JP, Touchard G, Bridoux F.

Nephrol Dial Transplant. 2016 May;31(5):850. doi: 10.1093/ndt/gfw056. Epub 2016 Mar 10. No abstract available.

PMID:
26968198
14.

Is there still a place for autologous stem cell transplantation in systemic AL amyloidosis with severe renal disease?

Bridoux F, Javaugue V, Fermand JP, Jaccard A.

Nephrol Dial Transplant. 2016 Aug;31(8):1199-202. doi: 10.1093/ndt/gfv460. Epub 2016 Feb 1. No abstract available.

PMID:
26908764
15.

Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma.

Fouquet G, Pegourie B, Macro M, Petillon MO, Karlin L, Caillot D, Roussel M, Arnulf B, Mathiot C, Marit G, Kolb B, Stoppa AM, Brechiniac S, Richez V, Rodon P, Banos A, Wetterwald M, Garderet L, Royer B, Hulin C, Benbouker L, Decaux O, Escoffre-Barbe M, Fermand JP, Attal M, Avet-Loiseau H, Moreau P, Facon T, Leleu X; IFM (Intergroupe Francophone du Myélome).

Ann Oncol. 2016 May;27(5):902-7. doi: 10.1093/annonc/mdw017. Epub 2016 Jan 19.

16.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, Rosiñol L, Straub J, Suvorov A, Araujo C, Rimashevskaya E, Pika T, Gaidano G, Weisel K, Goranova-Marinova V, Schwarer A, Minuk L, Masszi T, Karamanesht I, Offidani M, Hungria V, Spencer A, Orlowski RZ, Gillenwater HH, Mohamed N, Feng S, Chng WJ; ENDEAVOR Investigators.

Lancet Oncol. 2016 Jan;17(1):27-38. doi: 10.1016/S1470-2045(15)00464-7. Epub 2015 Dec 5.

17.

Patterns and effectiveness of bortezomib use according to age in the VESUVE cohort.

Grelaud A, Fourrier-Réglat A, Fitoussi O, Facon T, Jové J, Bénichou J, Robinson P, Marit G, Rouyer M, Moore N, Noize P; VESUVE Study Group.

Leuk Lymphoma. 2016;57(6):1349-54. doi: 10.3109/10428194.2015.1096354. Epub 2015 Nov 16.

PMID:
26397802
18.

The spectrum of neutrophilic dermatoses associated with monoclonal gammopathy: Association with IgA isotype and inflammatory profile.

Szalat R, Monsel G, Le Goff W, Battistella M, Bengouffa D, Schlageter MH, Bouaziz JD, Arnulf B, Vignon M, Lesnik P, Saussine A, Malphettes M, Lazareth A, Vignon-Pennamen MD, Bagot M, Brouet JC, Fermand JP, Rybojad M, Asli B.

J Am Acad Dermatol. 2015 Nov;73(5):809-20. doi: 10.1016/j.jaad.2015.07.031. Epub 2015 Sep 11. Review.

PMID:
26365596
19.

Prognostic value of kidney biopsy in myeloma cast nephropathy: a retrospective study of 70 patients.

Ecotière L, Thierry A, Debiais-Delpech C, Chevret S, Javaugue V, Desport E, Belmouaz S, Quellard N, Kaaki S, Goujon JM, Fermand JP, Touchard G, Bridoux F.

Nephrol Dial Transplant. 2016 Jan;31(1):64-72. doi: 10.1093/ndt/gfv283. Epub 2015 Aug 19.

PMID:
26289418
20.

MB4-2 breakpoint in MMSET combined with del(17p) defines a subset of t(4;14) multiple myeloma with very poor prognosis.

Lazareth A, Song XY, Coquin A, Harel S, Karlin L, Belhadj K, Roos-Weil D, Frenzel L, Tamburini J, Macro M, Chevret S, Loiseau HA, Minvielle S, Fermand JP, Soulier J, Bories JC, Arnulf B.

Haematologica. 2015 Nov;100(11):e471-4. doi: 10.3324/haematol.2015.127001. Epub 2015 Jul 23. No abstract available.

Supplemental Content

Loading ...
Support Center